Samsung Bioepis signs Teva partnership for SB41, SB44 biosimilars development and commercialization
Bitget2026/10/01 09:02- Samsung Bioepis signed an early-stage partnership with Teva to develop SB41 and SB44 biosimilars for commercialization.
- Bioepis will handle development, manufacturing, supply; Teva will lead sales in the US, Europe, Canada.
- Agreement signed Sept. 30, 2026; contract term and value were not disclosed.
- Bioepis expects receipts of at least KRW 41.8 billion, based on a 2.5% disclosure threshold versus 2025 financials.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SEI Price Prediction: Can SEI Rally From $0.06 to $1?
Japanese life insurance companies plan to increase holdings of Japanese government bonds, and demand for super-long-term JGBs is expected to improve.
Japan Post Insurance announced plans to increase its purchases of yen-denominated bonds, while Daido Life Insurance has raised its target for domestic bond holdings, focusing mainly on corporate bonds. Meiji Yasuda Life Insurance plans to keep its holdings of Japanese government bonds largely unchanged but will swap low-yield bonds for higher-yield varieties. This week, the 20-year government bond auction recorded a historic high bid-to-cover ratio, and life insurance institutions have been net buyers of super-long-term Japanese government bonds for four consecutive months.
Crypto prices
More
